Aurinia Pharmaceuticals (NASDAQ:AUPH) saw its shares surge 5.03% in Friday's intraday trading, following the company's release of its full-year 2024 financial results that exceeded analysts' earnings expectations.
The biotechnology firm reported revenue of $235.1 million for 2024, up 34% year-over-year and in line with estimates. However, Aurinia delivered a notable earnings beat, with earnings per share (EPS) of $0.04 surpassing analyst projections by 54%.
The strong earnings performance marked a significant turnaround for Aurinia, as the company reported a net income of $5.75 million in 2024, compared to a net loss of $78 million in the previous year. The company's profit margin also improved to 2.4%, up from a net loss position in 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。